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PERSPECTIVES IN CLINICAL NEPHROLOGY
Human immunodeficiency virus-associated glomeruloscierosis
The epidemic of human immunodeficiency virus (HIV) infec-
tion and the clinical picture of acquired immunodeficiency syn-
drome (AIDS) have revealed characteristic involvements of most
organs and organ systems, including the kidneys. Abnormalities in
fluid, electrolyte, and acid-base metabolism in patients infected
with HIV-i have been recognized and are the subjects of recent
reviews [1, 2]. However, most attention has focused on a distinct
pattern of structural renal disease that has come to be termed
HIV-associated nephropathy (HIVAN). This article will summa-
rize the features of this entity, emphasizing those aspects most
relevant to the practicing clinician.
Structural renal disease in patients infected with H1V
Although some early descriptions of renal involvement in
patients with AIDS documented a variety of parenchymal lesions
mostly involving glomeruli and characterized clinically by protein-
uria, these publications did not suggest a specific pattern of
involvement [3, 4]. However, in 1984 two separate reports drew
attention to patients in New York and Miami with proteinuria and
evidence of focal and segmental glomeruloscierosis (FSGS) on
renal biopsy [5, 6]; in addition, the report from Miami found a
large number of patients in whom mesangial prominence was the
primary histologic abnormality [6]. The authors from Downstate
Medical Center in New York went to some length to distinguish
HIV-associated FSGS from that arising as a result of intravenous
heroin use, so-called heroin nephropathy, since many of their
AIDS patients were intravenous drug users [5]. They pointed out
that progressive loss of renal function occurred at a much more
rapid pace in patients with HIVAN than in those with heroin
nephropathy despite the similarity in renal histologic lesions.
However, the report from Miami did not find a high incidence of
rapidly advancing renal failure, perhaps because their population
included a large number of patients whose main histological
abnormality was mesangial expansion rather than FSGS [6, 7].
These two centers updated their experience in 1987. At Down-
state Medical Center, 10% of AIDS patients had rapidly advanc-
ing renal failure; on renal biopsy, most had FSGS [8]. As a group
these patients did very poorly: of those enrolled in dialysis
therapy, only a small number left the hospital. The Miami group
drew attention to the propensity for HIVAN to affect certain
groups of AIDS patients [9], as will be discussed. As this clinical
experience mounted, the following picture of the components of
HI VAN began to emerge. Patients with HI VAN have proteinuria,
usually in the nephrotic range, and sometimes massive in magni-
tude. This is accompanied by renal insufficiency, which often
rapidly progresses to end-stage renal disease (ESRD), within
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three to six months, requiring treatment by means of dialysis.
Other clinical features observed frequently, but by no means
universally, include the presence of kidneys which are normal to
increased in size when examined by diagnostic ultrasound despite
being highly echogenic [10], the frequent absence of peripheral
edema expected from the nephrotic proteinuria [11, 12], and the
infrequency of hypertension accompanying the renal failure [13].
The increased kidney size and echogenicity are thought to relate
to some of the pathologic features of this entity (see below). The
explanation for the absence of edema in some patients despite
high-grade proteinuria is not known; although it has been sug-
gested that it may reflect the wasted, catabolic, and possibly
volume-depleted state of many of these patients [11, 12], other
wasted conditions such as kwashiorkor are accompanied by
edema. The unusually low incidence of hypertension in this group
of patients despite advanced renal insufficiency was documented
by Bourgoignie and colleagues [13]. Of 100 patients with HIVAN
seen at their institutions, diastolic blood pressure exceeded 100
mm Hg in only 15, which easily responded once these patients
underwent treatment with dialysis. Although the diagnosis of
HI VAN is usually made in patients with already identified AIDS-
defining diagnoses, cases have been observed in asymptomatic
HIV-infected patients, in whom the renal biopsy was felt to be
sufficiently characteristic to lead to HIV testing of the patients
[13—is].
Epidemiology of H1VAN
As this clinical picture of HIVAN developed, the identification
of certain associated risk factors soon became apparent. Patients
from Downstate Medical Center in Brooklyn with HI VAN shared
three features in large measure: they were African-American,
male, and most were intravenous heroin users [5, 8]. Thus, black
race, male gender and injection drug use as a mode of HIV
transmission were thought to be major risk factors for the
development of HIVAN. This was supported by experience in
Miami, where patients with HIVAN were 50% of injection drug
users (most of whom were black males) and much less commonly
male homosexuals [9]. A high incidence of HIVAN was also
observed in another center in New York [ii], and a composite
review of published experience as of 1990 identified 27% of
patients with HIVAN to have intravenous drug use as a risk factor
[16].
Because of the seeming association of HIVAN with injection
drug use, we queried whether HI VAN was indeed a specific entity
or merely reflected the occurrence of heroin-associated nephrop-
athy in African-American injection drug users who coincidentally
were infected with HIV-1. Experience at San Francisco General
Hospital indicated that HIV-infected patients had a variety of
clinical and histologic abnormalities of the kidneys, although
those progressing to ESRD were likely to be of black race and to
have injection drug use as a risk factor for HIV transmission; only
some of these could have had HIVAN [17]. As discussed below,
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logic features, and the latter is also a disease of black males [18].
Thus, some question was raised regarding the nature of clinical
renal disease in patients infected with HIV-1. This early experi-
ence from San Francisco General Hospital did not support the
existence of a specific HIV-related renal syndrome [17].
Subsequent clinical observations appear to have resolved this
conflict. Overall, well less than half of reported cases of HIVAN
have had injection drug use as a risk factor for HIV transmission
[16, 19]. Moreover, it has also occurred in Haitians, where HIV
infection occurs through heterosexual transmission, and in chil-
dren of HIV-infected mothers, where vertical transmission ac-
counts for HIV infection [9, 20]. However, the great majority of
reported cases have been of sub-Saharan African origin or
descent [16, 19, 21]. Thus, the mode of HIV transmission does not
appear to be a major risk factor for the development of HIVAN,
while black race has become evident as an important component
of this entity. More recent experience from San Francisco General
Hospital is consistent with this [22]. We have observed an
increased rate of referral of HIV-infected patients with structural
renal disease to our Division, many of whom had HIVAN on
clinical grounds although not undergoing renal biopsy. These
patients have been African-American, and this increase is related
to an increasing incidence of African-Americans with AIDS both
in the City of San Francisco and receiving treatment at San
Francisco General Hospital [22].
The reasons why black race may confer particular susceptibility
to HIVAN are not known. It may reflect a more general suscep-
tibility of African-Americans to all forms of kidney disease, the
basis for which is not currently understood [23, 24]. African-
Americans are also disproportionately victimized by AIDS [25],
although the high prevalence of HIVAN in African-Americans
compared to whites suggests that a specific interaction of HIV and
black race must be responsible. African-Americans exhibit a
different humoral response to HIV-1 p24 antigen than whites [26],
and could have other differences in the response to HIV-1
infection that relates to the development of HIVAN. This inter-
action could have a true genetic basis or could relate to a variety
of socioeconomic and cultural factors such as access to health
care, diet, and toxin exposure. The role of gender in risk for
HIVAN is more difficult to assess. Although most reported cases
have been in males, so have most reported cases of HIV infection.
Further study will be necessary to determine if male gender is a
separate risk factor for the development of HIVAN.
Pathology of HIVAN
The histological picture of HIVAN is characteristic [14, 15,
26—29]. The primary lesion is that of focal sclerosis of glomerular
tufts, with early involvement reflected by segmental distribution of
the sclerosis and later by global sclerosis. Glomerular capillary
walls are collapsed and retracted, leading to occlusion of lumens
in the areas involved in the sclerotic process. Cellular prolifera-
tion in glomeruli does not occur, but swelling of visceral epithelial
cells is common (Fig. 1). Mesangial expansion is seen in less
advanced cases and may be a forerunner of the sclerotic process,
although it may represent a separate clinical entity. A marked
degree of interstitial fibrosis occurs, felt in most cases to be out of
proportion in severity to the degree of glomerular involvement.
This is accompanied by patchy foci of mononuclear cell infiltrates.
Cystic tubular degeneration is widespread, with dilated tubular
lumens filled with proteinaceous eosinophilic material. A variable
degree of tubule cell necrosis has also been observed. Immunoflu-
orescent examination of renal tissue has shown deposition of
immunoglobulins, chiefly 1gM, and complement components pri-
marily in the areas of glomerular sclerosis with lesser staining in
the mesangium. The casts in tubular lumens contain immuno-
globulins, complement, light chains, albumin, and fibrin, but not
Tamm-Horsfall protein, although this protein is found in hyaline
casts in adjacent, undilated tubules [14]. Electron microscopic
changes confirm the glomerular sclerotic process and show wide-
spread effacement of foot processes of the visceral epithelial cells.
Characteristic tubuloreticular inclusions have been observed with
high frequency in glomerular and peritubular capillary endothelial
cells and invading leukocytes in the interstitium, and are regarded
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Fig. 1. Glomerulus from a patient with HWAN
showing global collapse of the glomerular
capilla,y walls and marked swelling of visceral
epithelial cells. Methenamine silver stain, x400.
From [28] with permission of the authors.
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Fig. 2. High-powered transmission electron
micrograph showing tubuloreticular structures in
perinuclear cisterns in a glomerular endothelial
cell of a patient with HI VAN. X14,000. From
[28] with permission of the authors.
as an important pathologic feature of HIVAN. Within the cells,
these inclusions have been identified in smooth and rough endo-
plasmic reticulum and in cisternae of the Golgi apparatus (Fig. 2).
Since these tubuloreticular inclusions are thought to reflect a
cellular response to viral infection [30], they have contributed to
speculation about the pathogenesis of HIVAN (see below).
Glomerular electron dense deposits have also been seen with
some regularity. These are thought to represent immune complex
formation or deposition; since FSGS is ordinarily not regarded as
an immune complex mediated glomerulonephritis, their occur-
rence may reflect another process(es). Attention has been drawn
to the occurrence of intranuclear bodies [27, 28]; however, their
significance has not been established.
As commented above, this pathologic picture has been viewed
as sufficiently characteristic as to warrant description as "a unique
combined glomerular, tubular, and interstitial lesion" [14] which
on occasion has led to the recognition of HIV-1 infection after the
fact [14, 15]. None of these pathologic features is seen only in
HIVAN; many are also observed in heroin-associated nephropa-
thy, including interstitial fibrosis and tubuloreticular inclusions
[31, 32], and there are many causes of FSGS [33]. Nevertheless,
the constellation of these histologic and ultrastructural changes
warrants characterization as a distinct pathological entity [12, 34].
The higher frequency and severity of these changes of HIVAN,
coupled with the occurrence of this entity in patients with HIV-1
infection who have no history of injection drug use (vertical
transmission from mother to child, heterosexually transmitted
infection, infection from transfusion of contaminated blood prod-
ucts), argue that the lesion is specifically related to HIV-1 and not
to some aspect of injection drug use. The clinical course of the two
entities also differs in some respects: more rapid progression to
ESRD, relative lack of hypertension, and preservation of normal
to enlarged kidney size are characteristic of HIVAN [8, 12, 13],
whereas heroin-associated nephropathy progresses more slowly, is
accompanied regularly by hypertension, and leads to small,
shrunken kidneys [4, 8, 35].
Although the clinical and histologic features of HIVAN may
permit its distinction from heroin-associated nephropathy, its
specificity and uniqueness for HIV-1 infection have been chal-
lenged. In a retrospective autopsy review of children dying with
immunodeficiency disorders (7 AIDS, 13 with severe combined
immunodeficiency, 6 with other forms of immunodeficiency),
Foster and colleagues observed some of the renal changes of
HIVAN, including FSGS, tubular ectasia and dilatation, and
tubular epithelial cell injury, in patients without HIV-1 infection
[36]. They suggested that the renal pathologic changes may reflect
the consequence of infection with some other virus(es). Although
provocative, this study suffers from its retrospective nature and
the lack of electron microscopic examination of kidney tissue.
Recent attention has also been drawn to a severe collapsing form
of FSGS, resembling HI VAN in most respects, in a group of adult
patients without HIV infection or known HIV risk factors [37].
Thirteen of 16 were African-American, most had nephrotic
proteinuria, and half progressed to ESRD or death within five
months. This picture resembles closely the picture of HIVAN
except that the patients gave no evidence of HIV infection. Renal
tissue also failed to reveal endothelial tubuloreticular structures
on electron microscopic examination [37]. This study underscores
the relationship between black race and severe FSGS, but also
calls into question the specificity of the lesion of HIVAN.
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Table 1. Clinical features of HIV-related renal disease
Circulating
Racial
predilection Proteinuria Hematuria Serum IgA
immune
complexes
Disease
progression
HIV-1
pathogenesis
HI V-associated nephropathy
FSGS Black Nephrotic Absent Normal Absent Rapid Yes
Mesangial hyperplasia ? Moderate Absent Not reported Not reported Slow ?
Immune complex
glomerulonephritis
IgA Nephropathy White Variable Present Elevated Present Slow Yes
IgG ? Variable Present Not reported Present Variable Yes
The occurrence of other forms of glomerular pathology, cou-
pled with the presence of glomerular electron-dense deposits in
kidneys of patients with HIV-1 infection, has led to the hypothesis
that HIV-infected patients may be at risk for immune complex
glomerulonephritis distinct from the FSGS of HIVAN. Particular
attention has been drawn to the occurrence of IgA nephropathy,
although nephritis associated with IgG deposition also occurs
[38—42]. Interestingly, many of these patients have also had
tubuloreticular inclusions detected on electron microscopy of
renal biopsy specimens [38—401. The immune complexes present
in the circulation and renal tissue in these cases have involved
HIV-1 antigens. The clinical presentation of these cases has
differed somewhat from cases of HIVAN in that the severity of
the proteinuria is variable and the clinical course more benign
(Table 1) [39, 40]. The occurrence of membranous nephropathy
secondary to chronic hepatitis B virus infection in the setting of
HIV infection has also been noted [43], as has the development of
a nephrotic syndrome due to secondary syphilis [44]. Other
glomerular lesions reported in AIDS patients include minimal
change nephropathy, membranoproliferative glomerulonephritis,
and a lupus-like diffuse proliferative glomerulonephritis [12, 17,
41]. The relationship of these lesions to the HIV-1 (or other)
infection is not established.
The major clinical features of HIVAN, mesangial hyperplasia,
and immune complex glomerulonephritis are distinguished in
Table 1. The predilection for white race, more moderate protein-
uria, presence of hematuria, and slow clinical progression differ-
entiate IgA nephropathy from HIVAN [45}, but the few cases of
IgG immune complex disease do not permit ready generalization.
Relative to HIV-related FSGS and mesangial hyperplasia, the
immune complex glomerulonephritides are uncommon. Nochy
and associates observed a marked degree of interstitial fibrosis
and scarring in some of their patients with immune complex
disease [41], a finding also observed by Kimmel et al [40}, and
indicating a mixed picture of immune complex disease with
elements of HIVAN.
Pathogenesis of IIIVAN
Although the mechanisms leading to renal disease in patients
infected with HIV-1 have not been fully elucidated, considerable
progress in this area has occurred in the past few years as a result
of studies in animal and cell culture models and clinical studies in
patients. It is appealing to speculate that human renal cells can
become infected with HIV-1. The initial report of Cohen et al
demonstrated viral genome and p24 protein in glomerular and
tubular epithelial cells of human renal biopsy specimens using in
situ hybridization and immunocytochemistry [46}. The failure of
another study to demonstrate viral antigens in kidney tissue of
patients with HI VAN is probably explained by a low viral burden
in their patients and the relative insensitivity of these methods
[47], since polymerase chain amplification has shown viral genome
to be present in kidneys of patients with HIVAN [48]. Mice
transgenic for a noninfective HIV-1 construct develop a renal
syndrome that closely resembles HIVAN in humans: they mani-
fest proteinuria and nephrotic syndrome as well as rapidly advanc-
ing renal failure. The kidneys show FSGS, microcystic tubular
dilatation, and interstitial fibrosis as well as the accumulation of
laminin, type IV collagen and heparan sulfate proteoglycan, all
components of the extracellular matrix [49]. When probed with a
cDNA designed to hybridize with all proviral mRNA's, viral genes
were found to be expressed in the kidneys of these transgenic mice
[49]. Thus, renal infection with this HIV-1 construct, and expres-
sion of its genes, led to the development of a renal lesion that
bears a striking similarity to the clinical picture of HIVAN,
making it attractive to speculate that HIVAN itself results from
direct infection of renal cells by HIV-1.
The situation is probably not that simple. Kimmel and associ-
ates used polymerase chain amplification of microdissected tissue
to show that glomeruli, tubules, and infiltrating inflammatory cells
from HIV-1-infected patients nearly uniformly contained viral
genome, and this was true whether or not the patients had clinical
evidence of renal disease or histologic evidence of FSGS [48].
These authors consequently suggested that the development of
HIVAN required a "triggering mechanism" in addition to viral
infection of renal tissue. The nature of such a triggering mecha-
nism is not known. To the extent that the transgenic mouse model
reflects human HIVAN, it must also be present in the mice, and
could conceivably be related simply to dose of virus or numbers of
infiltrating inflammatory cells. Alternatively, it could reflect a
difference between latent viral infection and the actual expression
of viral peptides. It could also have a connection to genetic
background in view of the high proportion of black patients with
HIVAN, as discussed above. It is also far from established that
productive infection with HIV-1 occurs in renal tissue or is related
to the development of renal disease. The observation just cited by
Kimmel and colleagues of viral genome in kidney tissue of AIDS
patients without any evidence of nephropathy [48] raises the
possibility that this material could be an "innocent bystander"
with no causal relationship to the development of tissue damage.
In vitro studies are equivocal. Green, Resnick and Bourgoignie
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provided evidence that glomerular mesangial and endothelial
cells, but not epithelial cells, in culture could be infected with
HIV-1 [50]. Of note, Cohen and Nast showed viral genome to be
present in epithelial but not mesangial cells of human renal
biopsies of patients with HIVAN using in Situ hybridization [14].
However, Alpers, McClure and Bursten were unable to demon-
strate infection of human mesangial cells in culture by several
strains of HIV-1 and HIV-2, although they did not use coculture
techniques that might have allowed detection of low level infec-
tion [51]. These investigators also found no evidence of CD4
expression, the putative portal of entry of HIV into the cell, in
their mesangial cell cultures [51]. An alternative possibility is that
HIV-infected macrophages take up residence in the kidney to
initiate a sequence of events leading to HIVAN [48, 52]. It is also
possible that elevated levels of cytokines, known to occur with
HIV-1 infection, may reach the kidneys via the circulation to
cause organ damage, although this mechanism by itself does not
appear adequate to account for the occurrence of HIVAN in
certain specific risk groups.
The mechanisms by which HIV-1 infection leads to renal
disease are not established but this topic has been the subject of
a recent editorial review in this journal [531. An attractive
hypothesis is that HIV-1 infection of renal cells results in in-
creased synthesis of transforming growth factor-n (TGF-/3). This
cytokine has been associated with fibrotic disease in other organs,
and is linked to glomeruloscierosis in numerous models of exper-
imental renal disease [54]. It possesses the remarkable property of
stimulating its own synthesis, and has profound effects on the
extracellular matrix: it induces the synthesis of numerous matrix
proteins, it down-regulates the synthesis of proteases acting on
matrix proteins, and it stimulates the expression of integrins,
important in matrix formation, on the cell surface [55]. These
properties make it appealing to suggest that HIVAN results from
unchecked synthesis of TGF-j3 following renal infection with
HIV-1 which then leads to fibrotic renal disease characterized by
FSGS and interstitial scarring and fibrosis. In support of this,
preliminary reports have indicated that TGF-p is significantly
increased in tubules of the transgenic mouse model [56], and in
glomeruli and the tubulointerstitium in kidney biopsies from
patients with HIVAN compared to disease controls or normal
kidneys [57, 58]. A recent study has also shown that incubation
with TGF-p of human mesangial cells transfected with the HIV-1
long terminal repeat (LTR) leads to increased expression of viral
genes [59]. The LTR contains regulatory sequences that stimulate
viral transcription [53]. Thus, one may speculate that renal
infection with HIV-1 initiates accelerated production of TGF-13
and possibly other cytokines [60]. TGF-3, in addition to a positive
feedback on its own synthesis, also stimulates viral replication. A
vicious cycle is established whereby viral infection is rapidly
increased within the kidney and extracellular matrix formation is
driven by ever higher levels of TGF-/3. Such a scheme could
account for the widespread glomerular and interstitial sclerosis
seen in kidneys of patients with HIVAN as well as the rapidly
advancing renal failure which occurs as a result of it. TGF-J3 also
causes hypertrophy of cultured rat mesangial cells [61], perhaps
offering an experimental analog for the mesangial prominence
seen in some patients with HIVAN [8, 9, 13]. Further investiga-
tion should establish whether this hypothesis has merit. It is
unlikely, however, that a TGF-f3-mediated mechanism accounts
for HIV-associated mesangial hyperplasia, since this lesion runs a
more benign course [45] and is not associated with widespread
glomerular and interstital fibrosis. It is also possible that HIV may
reach the kidney through invasion of CD4-positive lymphocytes!
macrophages to initiate the renal lesion [12, 52]. In addition,
elevated levels of circulating TGF-p have been observed in
patients infected with HIV-1 [62, 63], and could play a role in the
pathogenesis of the renal abnormalities of HIVAN. Consistent
with this, sera from HIV-1-infected patients, and supernatants
from cultures of infected macrophages, stimulated mesangial cell
proliferation and matrix production [64]. TGF-/3 would be a
candidate mediator of these effects. These relationships are
schematized in Figure 3.
Other disease mechanisms may also exist to account for im-
paired renal function in HIVAN. Langs and associates felt that
renal functional deterioration was more severe than expected
from examination of renal biopsy material in a group of patients
with HIVAN [29]. They consequently speculated that hemody-
namic changes could be contributing to the reduced GFR in their
patients. If so, this would at least offer the hope that some
intervention might correct the hemodynamic abnormality and
lead to an improvement in renal function. However, that has not
been the experience to date (see below). Patients infected with
HIV-1 who have immune complex glomerulonephritis may also
develop advanced renal insufficiency [40, 41]. Renal biopsies in
these patients show components of HIVAN as well as immune
complex deposition [40, 41], and the renal insufficiency cannot
clearly be attributed to one or the other process. Mechanisms by
which immune complexes affect the kidney have been recently
reviewed [65]. One report has linked renal infection with a rare
mycoplasma organism (Mycoplasma fermentans incognitus) to
HI VAN [66], although further work will be necessary to establish
the connection between this opportunistic infection and the
development of the renal abnormalities of HIVAN. Finally, the
possibility exists that other viruses may infect patients with
HIVAN and be related to the development of the renal disease.
HIV-1-infected patients have a high incidence of hepatitis virus
infection, and injection drug users are more likely to be infected
with human T-cell lymphotropic virus types I and II [67, 68].
However, with the exception of the recognized link between
hepatitis virus infection and glomerular disease [69—71], the
relationship between infection and renal disease, particularly
FSGS, has not been established.
Treatment and role of renal biopsy
At the present time, no therapeutic intervention has been
shown to have any benefit in arresting the progression of HIVAN.
In part this is due to the (usually) rapid progression to end-stage
renal disease (ESRD) limiting the time available for treatment
regimens, and in part it relates to the reluctance of most clinicians
to expose already immune-compromised HIV-1 infected patients
to therapeutic programs involving further immunosuppression for
other than short periods of time. Some evidence indicates a
benefit of long-term (several months) treatment with glucocorti-
coids in the management of idiopathic FSGS [72, 73], and a recent
report indicates that HIVAN may also respond to corticosteroid
treatment with an improvement in renal function and reduction in
proteinuria [74]. The steroid treatment was related to the devel-
opment of an opportunistic infection in one patient, but was well
tolerated in the others. Although the follow-up period was short,
and the number of patients small, this report opens up the
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possibility that some patients with HIVAN may benefit from
steroid therapy with an acceptably small risk of exacerbating their
underlying immune compromise. Further trials are warranted to
evaluate this treatment, and the NIH is developing a prospective
trial of prednisone in patients with HIVAN. More general mea-
sures also raise major treatment dilemmas. The possible value of
a protein-restricted diet in arresting the progressive renal failure,
although controversial [75, 76], poses serious problems for the
AIDS patient, in whom nutritional wasting is common and an
important goal of therapy is maximum nutritional support. Re-
cently, it has been suggested that treatment with zidovudine
ameliorates progressive HI VAN for a period of time [77—79]. This
has been based for the most part on anecdotal case reports in
individual patients and on a retrospective review. A preliminary
report of a larger series of patients from Downstate Medical
Center showed a better outcome in zidovudine-treated patients
compared to historical controls [80]. However, not all patients in
the treated group had evidence of HIVAN whereas all of the
historical controls were taken from an ESRD population, so this
study cannot answer the question of efficacy of this agent in
patients with HIVAN. If HIVAN does indeed result from renal
infection with HIV-1 as suggested above, then a benefit of
zidovudine, at least initially, might be expected much as this agent
has benefit in the generalized manifestations of HIV-1 infection.
The absence of proven effective therapy for HIVAN opens the
question of the value of renal biopsy in such cases. While the
decision regarding renal biopsy is always an individual one, several
general issues bear on the decision. First, a variety of glomerular
abnormalities in addition to FSGS have been observed in HIV-
1-infected patients, as summarized earlier, so the possibility that
one of these other lesions could account for the renal presentation
must be entertained. A few cases of minimal change nephropathy
/
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and other steroid-responsive lesions have been observed [12, 81,
82], at least one of which responded to short-term steroid therapy
without evident exacerbation of the underlying HIV-1 infection
after 16 months of follow-up [82]. In addition, steroid therapy may
prove to have a role in HIV-associated FSGS, as discussed earlier
[74]. Thus, renal biopsy helps to identify such patients, in whom a
treatment option exists. Second, a renal presentation of HIVAN
may be the initial clue to HIV-1 infection; in such patients, renal
biopsy may well be the stimulus leading to testing for HIV-1
infection. Third, asymptomatic patients with HIV-1 infection and
proteinuric renal disease may benefit from the prognostic value of
the definitive renal diagnosis based on renal biopsy. Fourth,
patients with AIDS are also at risk for the development of acute
renal failure [8, 12, 13, 17, 83]; although usually readily distin-
guishable on clinical grounds, renal biopsy may occasionally play
a role in this setting. Finally, the patient's own wishes regarding
his or her desire to know the exact pathological diagnosis will also
figure importantly in the decision to carry out a renal biopsy.
Because of the uniformly poor outcome of HIVAN to date, it is
desirable to identify other lesions which may follow a somewhat
better course. As discussed earlier, features favoring HIVAN
include typical ultrasonographic features of the kidneys, nephrot-
ic-range proteinuria, a bland urinary sediment, and the absence of
serologic markers of renal disease, while stable renal function with
nephrotic or low-grade proteinuria, kidneys of normal echogenic-
ity on ultrasound examination, hypertension, a nephritic urinary
sediment, and hypocomplementemia, a positive antinuclear anti-
body test, or other serologic abnormality, may all suggest the
presence of a renal disease other than HI VAN (Table 1). Patients
certainly exist who do not fall into one or the other of these
categories, and biopsy may be the only means to identify the
precise nature of the renal lesion. Renal biopsy is consequently of
value in approaching patients with renal involvement in the
setting of HIV-1 infection [42].
Experience has shown that patients with HIV-1 infection who
develop acute renal failure have a high likelihood of recovery and
should therefore be supported with hemodialysis if needed until
renal function is restored [8, 12, 13, 35, 84].
HIVand ESRD
Given the rapid and unrelenting loss of renal function in
HIVAN, and absence of any clearly effective treatment, most
patients will progress to end stage and require dialysis treat-
ment. This has been an area of some controversy, for several
reasons. There has been a real question whether dialysis is an
effective treatment option in this setting. The initial reports
indicated a very poor outcome in patients with overt AIDS and
HIVAN treated by means of hemodialysis [8, 85], with few
patients with opportunistic infections surviving on dialysis
more than six months. The possibility exists that opportunistic
infections may actually progress more rapidly in hemodialyzed
patients [12, 13, 86]. Although this initial dismal outcome may
have improved somewhat with recent advances in overall care
of the AIDS patient, most nephrologists have come to expect
only limited benefits with outpatient hemodialysis of patients
with AIDS and opportunistic infections. This bleak outlook has
stimulated discussion about whether hemodialysis should even
be offered to such patients [84, 86, 87]. Again, although no
mandate exists, arguments favor offering support with hemo-
dialysis for those informed patients with advanced AIDS who
request it [84, 86, 87].
The situation is much better in less advanced stages of HIV-1
infection. Patients with asymptomatic infection or AIDS-related
complex (ARC) do not deteriorate rapidly when placed on
hemodialysis: in the series by Ortiz and associates [85], 28 patients
with asymptomatic HIV-1 infection entered the hemodialysis
program. Of these, 7 died of non-HIV-related causes, and 7 others
progressed to ARC or AIDS after 276 81 days of dialysis. The
remaining 14 remained asymptomatic and alive on hemodialysis
488 75 days after commencing dialysis treatment. Thus, less
severe stages of HIV-1 infection carry a better prognosis on
hemodialysis.
Recent studies paint a similar picture for treatment with
peritoneal dialysis of ESRD in HIV-infected patients. Survival
is shorter in infected patients than noninfected patients treated
with this modality, and outcome is related to the stage of the
HIV infection [88, 89]. Infected patients had a higher rate of
peritonitis than noninfected controls in one series [89] but not
others [88, 90]. Theoretical arguments have been advanced for
advantages of home peritoneal dialysis over center-based he-
modialysis [91]. These include the possibility that the former
may cause less impairment of immune defense, and less
stimulation of HIV-1-infected T-cells, provide enhanced nutri-
tional support through glucose absorption from the dialysate,
and result in higher hematocrits, enabling increased use of
marrow-suppressing antiretroviral agents such as zidovudine.
To these theoretical advantages are added the more generally
accepted ones of reduced blood exposure and transmission of
infection. Drawbacks of peritoneal dialysis in AIDS patients
include the loss of albumin with each exchange, the possibility
of more frequent peritonitis, and a high rate of technique
failure [89, 90]. Technique failure usually results from progres-
sion of AIDS-related illnesses to the point where self-care is no
longer feasible. Serum albumin was a marker for morbid
complications in a general group of CAPD patients [92], and a
low serum albumin also correlated with shortened survival in
another group of HIV-infected patients with ESRD treated
with either peritoneal dialysis or hemodialysis [90].
Renal transplantation in HIV-1-infected patients with ESRD is
also a complex area. Experience is not large and is mostly
retrospective and anecdotal. It now appears clear that HIV-1 can
be transmitted by an infected organ [12], so that patients with high
risk behavior for HIV-1 infection are generally excluded as organ
donors [93]. Whether infection with HIV-1 should exclude a
patient from being considered as a transplant recipient has not
been established. Although case reports document the rapid
evolution of AIDS and early death in some recipients, attributed
to the immunosuppressive regimens employed to combat trans-
plant rejection, there are other examples where infected patients
have tolerated immunosuppression for long periods of time [93].
It is the position of a National Kidney Foundation-National
Institutes of Health task force that asymptomatic HIV-1 infection
should not deny consideration for transplantation and that trans-
plantation continue to be a treatment option for ESRD in such
patients until such time as it has been clearly established to be
contraindicated [94].
A number of other issues pertain to the management of the
ESRD patient with HIV-1 infection that are beyond the scope of
this Perspective. They include the risk of transmission of the virus
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in the dialysis setting, the techniques of infection control in the
dialysis unit, the question of testing of dialysis patients for HIV-1
infection, and dosing adjustments for AIDS-related medications
in the ESRD patient. The interested reader is referred to the
several excellent articles and reviews dealing with these topics [84,
86, 90, 94—96}.
Summary
The constellation of nephrotic proteinuria, FSGS, and rapid
loss of renal function in a patient infected with HIV-1 has been
sufficiently widespread and well documented to justify identifica-
tion as a specific renal syndrome, HIV-associated nephropathy.
The position paper of the National Kidney Foundation-National
Institutes of Health task force estimated in 1990 that 10,000 to
15,000 persons will develop renal disease in association with AIDS
[94]. Management of these patients is complex, and many will
reach ESRD and require dialysis treatment, posing additional
care problems. Greater understanding of the pathogenesis of the
renal disease should lead to treatments which will forestall the
development of HI VAN and possibly other forms of fibrotic renal
disease. The ultimate eradication of AIDS will consign this renal
syndrome to an interesting footnote in the history of nephrology.
Since that time is still far in the future, nephrologists will continue
to be faced with the need to diagnose and treat HIV-1-infected
patients with renal involvement.
MIcHnL H. HUMPHREYS
San Francisco, California, USA
Reprint requests to Michael H. Humphreys, MD., Box 1341, San Francisco
General Hospital, University of California San Francisco, San Francisco,
California 94143, USA.
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